Flatiron Health to Present Groundbreaking Research at IASLC 2025 World Conference on Lung Cancer Featuring Novel Gene Signature for Liver Metastasis in NSCLC and Insights on Real-World Treatment Patterns and Outcomes

Flatiron Health has announced that eight research studies utilizing its high-quality multimodal real-world data have been accepted for presentation at the IASLC 2025 World Conference on Lung Cancer in Barcelona, Spain. The presentations include both posters and e-posters, showcasing the company’s ongoing efforts to leverage advanced data analytics and responsible AI to drive insights in lung cancer care. Nathan Hubbard, Chief Business Officer at Flatiron Health, emphasized the transformative potential of AI in oncology. He stated that by combining robust real-world data from a global network of over five million people with cancer with responsible AI practices, the company is setting a new benchmark for evidence generation at scale. The research presented at WCLC 2025 aims to uncover treatment patterns, assess real-world effectiveness, and identify critical gaps where innovation is most needed. A key highlight is the first published study using the Flatiron Health–Caris Life Sciences Clinical-Molecular Database (CMDB), the largest and most comprehensive multimodal dataset of its kind. This research identified a novel gene signature capable of predicting the risk of liver metastasis in patients with advanced non-small cell lung cancer (NSCLC). By integrating detailed clinical records with deep molecular profiling, the findings offer clinicians a potential tool to identify high-risk patients early, enabling more personalized surveillance and treatment planning. Other notable presentations include: A study on biomarker testing and treatment initiation patterns in patients with resected early-stage NSCLC in the U.S. and U.K., highlighting disparities and opportunities in care delivery. Real-world outcomes of prophylactic cranial irradiation in extensive-stage small cell lung cancer patients receiving first-line immunotherapy and platinum-etoposide. Insights into survival outcomes in NSCLC using electronic health record data from the UK. An analysis of real-world progression-free survival as a surrogate endpoint for overall survival in NTRK-positive NSCLC and other advanced solid tumors, conducted in collaboration with Bristol-Myers Squibb and the University of Colorado Cancer Center. Findings from the ESSENCE study on evolving treatment patterns in extensive-stage small cell lung cancer, underscoring persistent unmet needs despite new therapies. A look at treatment trends in early-stage NSCLC in the U.S., supported by Lilly. A study on real-world treatment patterns and outcomes in patients with metastatic neuroendocrine neoplasms of the lung, in partnership with Merck & Co. The presentations will be featured across multiple sessions from September 7 to 9, 2025, in the Exhibit Hall and online. Flatiron Health invites stakeholders to schedule meetings during the conference and encourages following the company on X and LinkedIn for updates from #WCLC25. Flatiron Health, an independent affiliate of the Roche Group, continues to advance oncology care through data-driven innovation, machine learning, and real-world evidence. The company is committed to transforming patients’ real-life experiences into actionable knowledge to build a more connected and effective cancer care ecosystem.